Benefits of Omega-3 for Inflammation
Inflammation
Immune system and inflammatory response helps the body defend and
heal itself. But the immune system's response must be balanced, managing
the inflammatory response to prevent injury normal and otherwise healthy
tissue.
Omega-3 EPA and DHA from fish and fish oils can help. With the proper
amount of these, the anti-inflammatory response generated will create a
series healthy chemicals which curtail inflammation from injury,
infection, and aging, and help to maintain a healthy response to injury
and illness.
By incorporating See Yourself Well EPA and DHA into a treatment plan,
within 4-6 weeks a patient will:
- decrease in the pain of rheumatoid arthritis, osteoarthritis,
and general joint aches
- decrease in inflammatory biomarkers associated with liver
disease
- decrease in cataracts by 15%
- decrease risk of pneumonia by 35%
- decrease in breathing problems such as asthma
Dosage:*
In order to capture all of the risk factors indicated above, the
patient should consume 3 grams of combined See Yourself Well™
EPA and DHA omega-3 per day as follows:
- .5 of the 1,000mg capsules, OR
- .10 of the 500mg capsules, OR
- 1 teaspoon of the liquid oil
* Dosages are intended to cover all risk reductions listed and are
based on 600mg or 60% EPA /DHA concentrate of 1 gram of fish
oil.
Warning - Not All Omega 3s Are The Same:
Unless the Omega-3, which comes from. fish oil, is molecularly
distilled, it contains high levels of hazardous contaminants such as
mercury. See Yourself Well™
Professional Grade Omega-3 is ultra-refined and concentrated while
providing premium quality and optimum health benefit. All See Yourself
Well™ products are tested for
compliance with the standards set by the Council for Responsible
Nutrition and the World Health Organization and receive a 5-Star rating
from the International Fish Oil Standards Program.
( Available for
viewing at www.ifosprogram.com )
References
Berbert et ai, J. Of nutr., London State Univ. Brazil,
2005. Lopez-Garica et. AI., J. Nutr., 134: 1806-1811, 2004. Merchant et
aI., AJCN., 82- 668-674, 2005. Lu et aI., Am. J. Epid.,
161:948-959,2005. Miljanoiv et aI., AJCN. 82:887-893,2005. Mickleborough
et al. Am J. Respir. Crit. Care Med., 2003. Peat et aI., J. Allergy Clin
Immunology, 114(4):807813, 2004. Proc Natl Acad Sci USA. 2005 May
17;102(20):7133-8. Epub 2005 May 9. A. Richardson and P. Montgomery,
Pediatrics, 115: 1360-1366, 2005. Yuen et aI., Epilepsy and Behaviour,
7:253-258, 2005. Whalley, et aI., AJCN, 80: 1650-1657, 2004. Hibbeln,
NIH, 2005. Br J Cancer. 2003 Nov 3;89(9):1686-92. Augustsson et aI.,
Cancer Epid., Biomarkers, and Prev., 12: 64-67, 2003. Norat et aI., J.
Natl. Cancer Inst., 97:906-16, 2005. Simon et ai, AJE, 1995, also AHA
Statement, 2000. A.M. Gotto, Circ. 97:1027, 1998. Billman, GE, Proc.
Natl. Acad. Sci. 1994. LeMaitre et aI., AJCN, 77:319, 2003. He et aI.,
Stroke, 35: 1358-1542, 2004. Holub BJ., CMAJ, 166:609-615, 2002. |
|